NeoGenomics (NASDAQ:NEO) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS

NeoGenomics (NASDAQ:NEO) released its quarterly earnings data on Tuesday. The medical research company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), Zacks reports. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%.

NeoGenomics Stock Up 3.7 %

Shares of NEO stock opened at $14.42 on Tuesday. The firm’s fifty day moving average price is $15.70 and its two-hundred day moving average price is $15.59. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. NeoGenomics has a 1 year low of $12.13 and a 1 year high of $19.11. The firm has a market capitalization of $1.85 billion, a P/E ratio of -23.64 and a beta of 1.23.

Analysts Set New Price Targets

A number of research firms have issued reports on NEO. Jefferies Financial Group assumed coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price for the company. Bank of America boosted their price objective on NeoGenomics from $18.00 to $19.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a report on Friday, January 10th. The Goldman Sachs Group cut their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Benchmark downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, NeoGenomics has a consensus rating of “Moderate Buy” and a consensus price target of $20.20.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.